APR Applied Pharma Research S.A. and Labtec GmbH Announce Filing for Approval in Europe of Zolmitriptan Oral Dispersible Film (ODF)  
12/2/2010 9:33:04 AM

BALERNA, Switzerland & LANGENFELD, Germany & WARREN, N.J.--(BUSINESS WIRE)--APR, the drug developer and drug delivery technology provider headquartered in Balerna, Switzerland and its partner Labtec, the drug delivery technology developer headquartered in Langenfeld, Germany announce the submission of Zolmitriptan Oral Dispersible Film (ODF) for approval in Europe. The oral dispersible film strip formulation containing the renowned anti-migraine drug Zolmitriptan is the second prescription product based upon their RapidFilm® technology and is co-developed in collaboration with the Warren, New Jersey based Monosol Rx.